Furthermore, mRNA-sequencing provides insight on driving and co-occurring lesions (discussed later), specifically those amenable to targeted therapies with demonstrated efficacy in other diseases (e.g. FLT3 in Acute Myeloid Leukemia) [25]. This evidence concerns the gene FLT3 and acute myeloid leukemia.